M. Shiffman

1.2k total citations
45 papers, 763 citations indexed

About

M. Shiffman is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, M. Shiffman has authored 45 papers receiving a total of 763 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hepatology, 24 papers in Epidemiology and 9 papers in Surgery. Recurrent topics in M. Shiffman's work include Hepatitis C virus research (24 papers), Liver Disease Diagnosis and Treatment (16 papers) and Hepatitis B Virus Studies (15 papers). M. Shiffman is often cited by papers focused on Hepatitis C virus research (24 papers), Liver Disease Diagnosis and Treatment (16 papers) and Hepatitis B Virus Studies (15 papers). M. Shiffman collaborates with scholars based in United States, France and Italy. M. Shiffman's co-authors include Edward W. Moore, J. M. Kellum, H J Sugerman, William H. Brewer, E. Läwitz, Patrick Marcellin, John G. McHutchison, M. Rodríguez‐Torres, Mark Sulkowski and Diethelm Messinger and has published in prestigious journals such as Gastroenterology, Hepatology and Journal of Hepatology.

In The Last Decade

M. Shiffman

40 papers receiving 732 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Shiffman United States	14	436	375	343	174	54	45	763
A Rafecas Spain	13	468 1.1×	426 1.1×	257 0.7×	93 0.5×	33 0.6×	51	683
G.A. Makar United States	14	341 0.8×	265 0.7×	326 1.0×	107 0.6×	43 0.8×	33	636
Eleazar Chaib Brazil	16	410 0.9×	553 1.5×	209 0.6×	95 0.5×	84 1.6×	101	791
Anna–Liisa Karvonen Finland	15	312 0.7×	320 0.9×	344 1.0×	136 0.8×	13 0.2×	18	626
Antonio Rafecas Spain	14	578 1.3×	558 1.5×	268 0.8×	120 0.7×	65 1.2×	25	849
Sara Lorente Spain	12	290 0.7×	263 0.7×	155 0.5×	64 0.4×	38 0.7×	24	518
J Wong Hong Kong	16	358 0.8×	600 1.6×	222 0.6×	340 2.0×	13 0.2×	24	850
Cheng‐Kun Wu Taiwan	15	281 0.6×	273 0.7×	302 0.9×	99 0.6×	10 0.2×	57	662
Guilherme Eduardo Gonçalves Felga Brazil	15	425 1.0×	439 1.2×	287 0.8×	54 0.3×	55 1.0×	36	732
Haldun Selçuk Türkiye	14	172 0.4×	217 0.6×	207 0.6×	93 0.5×	11 0.2×	55	477

Countries citing papers authored by M. Shiffman

Since Specialization

Citations

This map shows the geographic impact of M. Shiffman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Shiffman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Shiffman more than expected).

Fields of papers citing papers by M. Shiffman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Shiffman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Shiffman. The network helps show where M. Shiffman may publish in the future.

Co-authorship network of co-authors of M. Shiffman

This figure shows the co-authorship network connecting the top 25 collaborators of M. Shiffman. A scholar is included among the top collaborators of M. Shiffman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Shiffman. M. Shiffman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shea, Patrick R., Gideon M. Hirschfield, M. Shiffman, et al.. (2017). Common variation near glial-derived neurotrophic factor is associated with progression of hepatic collagen content in a genome-wide association study of liver fibrosis phenotypes in patients with primary sclerosing cholangitis. Journal of Hepatology. 66(1). S4–S5. 1 indexed citations

Kadayıfçı, Abdurrahman, George Papatheodoridis, MF Yuen, et al.. (2015). Characterization of HBsAg decline in the Tenofovir disoproxil fumarate (TDF) and peginterferon alfa 2A (PEG) combination study for chronic hepatitis B (CHB). Hepatology International. 1 indexed citations

Sulkowski, Mark, M. Rodríguez‐Torres, E. Läwitz, et al.. (2012). 1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS. Journal of Hepatology. 56. S560–S560. 37 indexed citations

O’Brien, T., Herbert L. Bonkovsky, R. Pfeiffer, et al.. (2010). 1174 ASSOCIATION OF IL28B GENOTYPE WITH VIROLOGICAL RESPONSE TO PEGYLATED-INTERFERON PLUS RIBAVIRIN IN PATIENTS WITH ADVANCED CHRONIC HEPATITIS C ENROLLED IN THE HALT-C TRIAL. Journal of Hepatology. 52. S454–S454.

Sulkowski, Mark, M. Shiffman, Jonathan McCone, et al.. (2009). 126 HEMOGLOBIN DECLINE IS ASSOCIATED WITH SVR AMONG HCV GENOTYPE 1-INFECTED PERSONS TREATED WITH PEGINTERFERON (PEG)/RIBAVIRIN (RBV): ANALYSIS FROM THE IDEAL STUDY. Journal of Hepatology. 50. S51–S52. 3 indexed citations

Shiffman, M., E. Läwitz, A. Zaman, et al.. (2009). 643 PEG-IFN-l: ANTIVIRAL ACTIVITY AND SAFETY PROFILE IN A 4-WEEK PHASE 1B STUDY IN RELAPSED GENOTYPE 1 HEPATITIS C INFECTION. Journal of Hepatology. 50. S237–S237. 17 indexed citations

Bacon, B.R., et al.. (2009). 1049 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY OF NITAZOXANIDE PLUS PEGINTERFERON AND RIBAVIRIN IN HCV GENOTYPE 1 PATIENTS: INTERIM ANALYSIS SHOWS INCREASE IN EVR. Journal of Hepatology. 50. S381–S381. 11 indexed citations

Sulkowski, Mark, E. Läwitz, M. Shiffman, et al.. (2008). 991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY. Journal of Hepatology. 48. S370–S371. 29 indexed citations

Nelson, Daniel, Paul J. Pockros, Eliot Godofsky, et al.. (2008). 993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN. Journal of Hepatology. 48. S371–S371. 23 indexed citations

10.

Hadziyannis, S., et al.. (2008). 7 RAPID VIROLOGICAL RESPONSE IS A MORE IMPORTANT PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE (SVR) THAN GENOTYPE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION. Journal of Hepatology. 48. S5–S5. 21 indexed citations

11.

Pockros, Paul J., et al.. (2007). [632] IMPACT OF TARIBAVIRIN EXPOSURE ON EFFICACY, ANEMIA RATES, AND Gl SIDE EFFECTS WHEN USED WITH PEGYLATED INTERFERON ALFA-2b FOR THE TREATMENT OF CHRONIC HEPATITIS C. Journal of Hepatology. 46. S239–S239. 2 indexed citations

12.

Shiffman, M., et al.. (2005). HCV Core Protein Augments Cyclosporine Immunosuppression. Transplantation Proceedings. 37(2). 652–653. 13 indexed citations

13.

Shiffman, M., Patrick Marcellin, L. Jeffers, et al.. (2004). 45 HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients. Journal of Hepatology. 40. 17–17. 12 indexed citations

14.

Sterling, Richard K., Velimir A. Luketic, Arun J. Sanyal, et al.. (2003). 100 A prospective, randomized controlled pilot study of ursodeoxycholic acid (UDCA) combined with mycophenolate mofetil (MMF) in the treatment of primary sclerosing cholangitis. Hepatology. 38. 204–204. 1 indexed citations

15.

Shiffman, M., Jenny Heathcote, Robert G. Gish, et al.. (2003). Long-term safety beyond 48 weeks of adefovir dipivoxil (ADV) 10 Mg once daily for chronic hepatitis B (CHB): An integrated analysis of two phase III studies. Gastroenterology. 124(4). A709–A709. 1 indexed citations

16.

Shiffman, M., et al.. (2002). Living donor liver transplantation: Summary of a conference at The National Institutes of Health. Liver Transplantation. 8(2). 174–188. 103 indexed citations

17.

Fisher, Robert A., M. P. Posner, M. Shiffman, et al.. (1999). Adenosine rinse in human orthotopic liver transplantation: results of a randomized, double-blind trial.. PubMed. 1(1). 55–66. 6 indexed citations

18.

Luketic, Velimir A., M. Shiffman, Arun J. Sanyal, et al.. (1998). Long-term, Low Dose, Passive Immunoprophylaxis with HBIg Effectively Prevents Recurrence of Hepatitis B Infection after Liver Transplantation. Transplantation. 65(12). S49–S49. 1 indexed citations

19.

Shiffman, M.. (1996). Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology. 24(1). 21–26. 1 indexed citations

20.

Shiffman, M.. (1995). The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the National Digestive Diseases Advisory Board. Hepatology. 22(5). 1591–1597. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact